Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- MHLW Calls for Fair-Price Distribution of Drugs Subject to Unprofitability Re-Pricing
March 6, 2023
- SCARDA to Invite Funding Applications for New Modality Research without Requiring PI Plans
March 3, 2023
- LDP Taskforce Begins Social Security Debates towards Honebuto
March 3, 2023
- MHLW Unveils New List Prices for FY2023 Revision, Ad-Hoc PMP Raise for 143 Products
March 3, 2023
- Komeito Petitions Govt for Market Incentives for Meiji’s Novel Antibacterial
March 2, 2023
- LDP League to Compile Final Proposal for SaMD Reimbursement This Spring
March 2, 2023
- Shelf Life of Ronapreve, Xevudy Extended to 30 Months in Japan
March 1, 2023
- Japan Panel Backs Approval of 1st Nasal Flu Vaccine
February 28, 2023
- Pfizer’s Omicron-Adapted Jab for Ages 5-11 in Line for Japan Approval
February 28, 2023
- Nipro Pharma Told to Improve Biz over Violations Spanning 42 Products, Faked Records
February 27, 2023
- Japan Approves Precedex for Pediatric Use, Expands Labels for Nubeqa, Rinvoq, and More
February 27, 2023
- PMDA Reviewing 16 APIs for Paradoxical Drug Reaction
February 27, 2023
- Komeito Poised to Call for Govt Support on Meiji Pharma’s Nacubactam
February 27, 2023
- Japan Panel OKs Plan to Offer 2 Boosters for Elderly in FY2023; Program to Start from May
February 24, 2023
- Alexion’s Danicopan, Pfizer’s Elranatamab and 2 More APIs Get Orphan Tag
February 24, 2023
- Nipro Pharma Likely to Face Business Improvement Order over Violations
February 24, 2023
- MHLW Panel Maintains Caution against Xocova Use in Women Who Might Be Pregnant
February 22, 2023
- MOF to Work with Industry to Boost Drug Discovery, Minister Says on Trade Deficit
February 22, 2023
- MHLW to Launch SaMD Working Group to Compile Opinions by Summer
February 22, 2023
- Consider Special Characteristics of Patches If Govt Is to Revise LLP Pricing Rules: LDP League
February 21, 2023
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…